Redesigned

Abgentis News

  • Abgentis' Lead programme demonstrates efficacy against multi-drug resistant Gram-negatives

    GYR12, Abgentis' lead novobiocin analogue, in combination with colistin, is effective against colistin-resistant strains of E. coli, K. pneumoniae and A. baumannii. Sub-microgramme per ml concentrations of GYR12 with 2 ug/ml of colistin kill strains that are resistant to either compound alone. Colistin-resistant (MIC >256 ug/ml colistin) can be fully resensitised and killed.

    The GYR12/colistin combination provides a broad-spectrum opportunity which Abgentisis evaluating through detailed preclinical studies.

    1 Comment

    • 1. May 9 2017 12:27PM by Saravanan

      Abgentisis is a leading pharma company and it's research in antibacterials are impressive.

Abgentis News

You are viewing the text version of this site.

To view the full version please install the Adobe Flash Player and ensure your web browser has JavaScript enabled.

Need help? check the requirements page.


Get Flash Player